非酒精性脂肪性肝病患者血清TIMP3、系统免疫炎症指数变化及其与颈动脉粥样硬化的关系研究

摘要/Abstract

摘要： 目的探究非酒精性脂肪性肝病(NAFLD)患者血清组织抑制金属蛋白酶3(TIMP3)水平及系统免疫炎症指数(SII)水平,并评估其与颈动脉粥样硬化(CAS)之间的关系。方法纳入2021年10月至2023年9月期间在安康市中心医院诊治的149例NAFLD患者,所有患者均进行腹部超声检查和血清TIMP3、SII检测。依据颈动脉超声检查结果,患者分为CAS组和非CAS组。比较两组间TIMP3和SII水平的差异,并进行NAFLD患者发生CAS的多因素分析。分析TIMP3和SII水平对NAFLD患者发生CAS的预测效能。结果 CAS组BNP 、TC、TG 、LDL-C水平分别是(186.49±19.39)pg/mL、(5.32±0.73) mmol/L、(2.43±0.62) mmol/L、(3.18±0.77) mmol/L,均高于非CAS组(P<0.05) ;CAS组HDL-C 水平为(1.03±0.35) mmol/L,低于对照组(P<0.05)。CAS组TIMP3 水平为(159.62±22.63) pg/mL,低于对照组(P<0.05);CAS组SII为(1 035.26±182.15),高于对照组(P<0.05)。将上述差异有统计学意义的指标水平均作为自变量纳入logistic多因素回归分析,发现BNP、TC、TG、HDL-C、LDL-C、TIMP3 、SII均为NAFLD患者发生CAS的影响因素(P<0.05)。结论合并CAS的NAFLD患者血清TIMP3水平降低,SII水平升高,该发现为NAFLD 相关 CAS的早期诊断和干预提供了新的研究方向。

关键词: 非酒精性脂肪性肝病, 血清组织抑制金属蛋白酶3, 系统免疫炎症指数, 颈动脉粥样硬化

Abstract: Objective To investigate the serum levels of tissue inhibitor of metalloproteinase 3 (TIMP3) and systemic immune inflammation index (SII) in patients with non-alcoholic fatty liver disease (NAFLD), and to assess their relationship with carotid artery atherosclerosis (CAS). Methods A total of 149 NAFLD patients treated in our hospital from October 2021 to September 2023 were enrolled in this study. All patients underwent abdominal ultrasound examination and serum TIMP3 and SII testing. Based on carotid ultrasound results, the patients were divided into a CAS group and a non-CAS group. Statistical methods were used to compare the differences in TIMP3 and SII levels between the two groups, and a multivariate analysis of factors influencing CAS occurrence in NAFLD patients was performed. The predictive value of TIMP3 and SII levels for the development of CAS in NAFLD patients was also analyzed. Results In the CAS group, BNP, TC, TG, and LDL-C levels were(186.49±19.39) pg/mL,(5.32±0.73)mmol/L, (2.43±0.62)mmol/L, and (3.18±0.77) mmol/L, respectively, which were significantly higher than those in the control group(P<0.05). The HDL-C level in the CAS group was (1.03±0.35)mmol/L, significantly lower than that in the control group (P<0.05). The TIMP3 level in the CAS group was (159.62±22.63)pg/mL, significantly lower than that in the control group (P<0.05); the SII in the CAS group was 1 035.26±182.15, significantly higher than the control group (P<0.05). After incorporating these differential indicators as independent variables in the logistic multivariate regression analysis, BNP, TC, TG, HDL-C, LDL-C, TIMP3, and SII were identified as factors influencing the occurrence of CAS in NAFLD patients (P<0.05). Conclusion In NAFLD patients who develop CAS, serum TIMP3 levels are reduced while SII levels are elevated. TIMP3 and SII may serve as potential biomarkers for carotid artery atherosclerosis in NAFLD patients, providing new directions for early diagnosis and intervention.

Key words: Non-alcoholic fatty liver disease, Serum tissue inhibitor of metalloproteinase 3, Systemic immune inflammation index, Carotid artery atherosclerosis

王桢哲, 薛麟, 张熙. 非酒精性脂肪性肝病患者血清TIMP3、系统免疫炎症指数变化及其与颈动脉粥样硬化的关系研究[J]. 肝脏, 2026, 31(3): 433-437.

WANG Zhen-zhe, XUE Lin, ZHANG Xi. Study on the changes of serum TIMP3 and systemic immune inflammation index in non-alcoholic fatty liver disease patients and their relationship with carotid artery atherosclerosis[J]. Chinese Hepatolgy, 2026, 31(3): 433-437.

/ 推荐

参考文献

[1] Tincopa M A, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Lancet Gastroenterol Hepatol, 2023, 8(7): 660-670.
[2] Kuang J, Wang J, Li Y, et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis[J]. Cell Metab, 2023, 35(10): 1752-1766. e8.
[3] Younossi Z M, Paik J M, Stepanova M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease[J]. J Hepatol, 2024, 80(5): 694-701.
[4] Benson J C, Saba L, Bathla G, et al. MR Imaging of carotid artery atherosclerosis: updated evidence on high-risk plaque features and emerging trends[J]. AJNR Am J Neuroradiol, 2023, 44(8): 880-888.
[5] Hutcherson C W, Mao M, Thakur B, et al. Low-grade inflammatory mediators and metalloproteinases yield synchronous and delayed responses to mechanical joint loading[J]. Cartilage, 2024, 15(4): 417-427.
[6] Xia Y, Xia C, Wu L, et al. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: a 20-year follow-up cohort study of 42,875 US adults[J]. J Clin Med, 2023, 12(3): 1128.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南 (2018年版)[J]. 实用肝脏病杂志,2018,21(2):177-186.
[8] 中华医学会外科学分会血管外科学组. 颈动脉狭窄诊治指南[J]. 中国血管外科杂志(电子版),2017,2(3):169-175.
[9] Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease[J]. J Hepatol, 2023, 78(5): 1048-1062.
[10] Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options[J]. Cardiovasc Res, 2023, 119(9): 1787-1798.
[11] Govaere O, Hasoon M, Alexander L, et al. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures[J]. Nat Metab, 2023, 5(4): 572-578.
[12] 李艳,韩丽. 血清B型脑钠肽、胰岛素样生成因子结合蛋白-3水平与非酒精性脂肪肝患者心房颤动的关系[J]. 实用临床医药杂志,2024,28(7):101-105,109.
[13] Le M H, Le D M, Baez T C, et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1 201 807 persons[J]. Hepatology, 2023, 79(2): 287-295.
[14] 周敏,成少华,葛昌玲. 血清Nrf2和TIMP3水平在川崎病早期诊断及预后中的意义[J]. 四川医学,2023,44(12):1299-1303.
[15] Hussein R, Aboukhamis I. Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis[J]. Heliyon, 2023, 9(3).
[16] Delrue C, Speeckaert M M. Tissue inhibitor of metalloproteinases-2 (TIMP-2) as a prognostic biomarker in acute kidney injury: a narrative review[J]. Diagnostics, 2024, 14(13): 1350.
[17] Jia D, Ping W, Wang M, et al. SIRT1 mediates the inflammatory response of macrophages and regulates the TIMP3/ADAM17 pathway in atherosclerosis[J]. Exp Cell Res, 2024, 442(2):114253.
[18] Wang H, Nie H, Bu G, et al. Systemic immune-inflammation index (SII) and the risk of all-cause, cardiovascular, and cardio-cerebrovascular mortality in the general population[J]. Eur J Med Res, 2023, 28(1):575.
[19] 郑波,哈丽达·夏尔甫哈孜,谈理. 非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究[J]. 实用肝脏病杂志,2024,27(2):198-201.
[20] Wang C, Xu H, Liao X, et al. Hypertension promotes the proliferation and migration of ccRCC cells by downregulation of TIMP3 in tumor endothelial cells through the miR-21-5p/TGFBR2/P38/EGR1 axis[J]. Mol Cancer Res, 2023, 21(1):62-75.